The Technical Analyst
Omeros Corp [OMER]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Omeros Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.16% $3.09
America/New_York / 24 apr 2024 @ 13:10
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 178.75 mill |
| EPS: | -2.79 |
| P/E: | -1.110 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 57.94 mill |
| Avg Daily Volume: | 0.504 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Neutral | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.110 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.19x |
| Company: PE -1.110 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.79 - 3.38 ( +/- 9.53%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-17 | Demopulos Gregory A Md | Buy | 15 000 | Common Stock |
| 2023-11-15 | Demopulos Peter A Md | Buy | 10 000 | Common Stock |
| 2023-11-14 | Demopulos Gregory A Md | Buy | 25 000 | Common Stock |
| 2023-11-13 | Demopulos Gregory A Md | Buy | 37 500 | Common Stock |
| 2023-09-22 | Demopulos Gregory A Md | Buy | 715 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 97.84 |
| Last 99 transactions |
| Buy: 3 182 539 | Sell: 554 578 |
Forecast:
14:49 - $3.07
Live Trading Signals (every 1 min)
Forecast
1: 13:19 - $3.09
Forecast 2: 14:09 - $3.08
Forecast 3: 14:49 - $3.07
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.09 (-0.16% ) |
| Volume | 0.124 mill |
| Avg. Vol. | 0.504 mill |
| % of Avg. Vol | 24.55 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OMER
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:33 | sell | $3.34 | N/A | Active |
|---|
OMER
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Latest Press Releases
2024-03-27 08:30:00 - Press Release
Omeros Corporation To Announce Fourth Quarter And Year-end Financial Results On April 1, 2024
Seattle--(business wire)--omeros corporation (nasdaq: omer), today announced that the company will issue its financial results for the quarter and year ended december 31, 2023, on monday, april 1, 2024, after the market closes. omeros management will host a conference call and webcast that same day at 4:30 p.m. eastern time (1:30 p.m. pacific time) to discuss the financial results as well as recent developments and highlights. conference call details for online access to the live webcast of the.
2024-02-01 09:11:00 - Press Release
Omeros Corporation Announces Additional Royalty Monetization With Dri Healthcare Trust
Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced the sale to dri healthcare acquisitions lp (“dri”), a wholly owned subsidiary of dri healthcare trust, of an expanded interest in certain royalty payments based on net sales of omidria in the united states. omidria, a novel ophthalmic product for use in cataract and lens replacement surgery, was invented and first commercialized by omeros. in december 2021, omeros sold omidria and related business assets to rayner surgi.
2023-11-09 16:02:00 - Press Release
Omeros Corporation Reports Third Quarter 2023 Financial Results
Seattle--(business wire)--omeros corporation (nasdaq: omer), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the third quarter ended september 30, 2023, which inc.
2023-11-06 08:00:00 - Press Release
Omeros Corporation To Announce Third Quarter Financial Results On November 9, 2023
Seattle--(business wire)--omeros corporation (nasdaq: omer), today announced that the company will issue its financial results for the quarter ended september 30, 2023, on thursday, november 9, 2023, after the market closes. omeros management will host a conference call and webcast that same day at 4:30 p.m. eastern time (1:30 p.m. pacific time) to discuss the financial results as well as recent developments and highlights. conference call details for online access to the live webcast of the co.
2023-11-03 09:05:00 - Press Release
Omeros Announces Online Publication In Advance Of Ash Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use Of 15 Patients With Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (ta-tma), 14 of whom had “high-risk” ta-tma. narsoplimab is omeros' investigational antibody targeting masp-2, the effector enzyme of the lectin pathway of the complement system. the report was authored by an external group of investigators i.
Latest News
2024-04-01 20:09:09 - Seeking Alpha
Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript
2024-03-17 10:02:00 - InvestorPlace
Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade
Hidden gems often remain undiscovered within the labyrinth of the stock market. Three stocks with massive upside stand out among the several alternatives as possible titans with significant upside potential.
2024-02-07 09:34:32 - InvestorPlace
3 Sleeper Stocks Under $15 Ready to Explode by 2029
In general, high-growth stocks and sleeper stocks under $15 are associated with valuation concerns. Let's forget inflated giants and overhyped darlings.
2023-12-24 13:08:45 - InvestorPlace
7 Short-Squeeze Stocks That Are Screaming for Speculation
While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it's time to address this speculative practice under a three-dimensional lens.
2023-11-27 01:18:10 - Seeking Alpha
Omeros: Why It Is Worthwhile To Bet On Narsoplimab
Omeros Corporation focuses on small-molecule and antibody drugs for common disorders and rare diseases. The company has prioritized the resubmission of its BLA for Narsoplimab for TA-TMA treatment and is advancing Phase-3 clinical trials for MASP-3 inhibitor OMS906. Narsoplimab holds promise for treating TA-TMA, COVID-19, and Lupus Nephritis but faces competition in the latter two conditions.
2023-10-16 08:02:11 - Reuters
Omeros to terminate kidney disease trial as therapy fails late-stage study
Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of the late-stage study.
2023-08-04 08:00:00 - Business Wire
Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2023, on Wednesday, August 9, 2023, before the market opens. Omeros management will host a conference call and webcast that same day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conferen.
2023-07-21 17:06:20 - Seeking Alpha
Omeros Corporation - Still Looking Too Risky For A Buy Rating
Omeros Corporation's share price has seen significant run-ups in recent months despite disappointing first quarter results in 2023 and the company's lack of profitability. The company was awarded $6.69 million from the National Institute on Drug Abuse for its program OMS527, which focused on the treatment of cocaine use disorder. However, it also has $344 million in long-term debts. Omeros' future heavily relies on FDA approval of its drug candidates, particularly Narsoplimab, and faces intense competition in the biopharmaceutical sector.
2023-06-21 08:30:00 - Business Wire
Omeros Announces Webcast Details for Annual Meeting of Shareholders
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 23, 2023, starting at 10:00 a.m. Pacific Time. A live webcast of the Annual Meeting of Shareholders can be accessed through www.virtualshareholdermeeting.com/OMER2023. A general corporate overview and question and answer session is expected to follow the business portion of the annual meeting. A.
2023-06-12 14:47:56 - The Motley Fool
Why Shares of Omeros Dropped on Monday
The company's lead therapy, Narsoplimab, has not yet been approved. As of the first quarter, Omeros had $371.4 million in cash.